Last reviewed · How we verify

Moxam — Competitive Intelligence Brief

Moxam (latamoxef) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: latamoxef. Area: Metabolic.

marketed latamoxef Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI Metabolic Live · refreshed every 30 min

Target snapshot

Moxam (latamoxef) — Eli Lilly.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Moxam TARGET latamoxef Eli Lilly marketed latamoxef Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center marketed Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (latamoxef class)

  1. Eli Lilly · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxam — Competitive Intelligence Brief. https://druglandscape.com/ci/latamoxef. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: